<SEC-DOCUMENT>0001193125-19-010961.txt : 20190117
<SEC-HEADER>0001193125-19-010961.hdr.sgml : 20190117
<ACCEPTANCE-DATETIME>20190117073002
ACCESSION NUMBER:		0001193125-19-010961
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20190117
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190117
DATE AS OF CHANGE:		20190117

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ZAFGEN, INC.
		CENTRAL INDEX KEY:			0001374690
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				203857670
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36510
		FILM NUMBER:		19530065

	BUSINESS ADDRESS:	
		STREET 1:		175 PORTLAND STREET
		STREET 2:		4TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02114
		BUSINESS PHONE:		617-622-4003

	MAIL ADDRESS:	
		STREET 1:		175 PORTLAND STREET
		STREET 2:		4TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02114

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ZAFGEN INC
		DATE OF NAME CHANGE:	20060906
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d655163d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of Earliest Event Reported): January&nbsp;17, 2019 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Zafgen, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact
name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>DELAWARE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">001-36510</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">20-3857670</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File&nbsp;Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification&nbsp;No.)</B></P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>175 Portland Street, 4th Floor</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Boston, Massachusetts</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>02114</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code
<FONT STYLE="white-space:nowrap">(617)&nbsp;622-4003</FONT> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Not Applicable </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former name or former address, if changed since last report) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting material pursuant to <FONT STYLE="white-space:nowrap">Rule&nbsp;14a-12</FONT> under the Exchange Act
(17 CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to <FONT
STYLE="white-space:nowrap">Rule&nbsp;14d-2(b)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to <FONT
STYLE="white-space:nowrap">Rule&nbsp;13e-4(c)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this
chapter) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 <FONT STYLE="white-space:nowrap">(&#167;240.12b-2</FONT> of this chapter). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Emerging growth company&nbsp;&nbsp;&#9746; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an
emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange
Act.&nbsp;&nbsp;&#9746; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;7.01</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Regulation FD Disclosure. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;17, 2019, Zafgen, Inc. (the &#147;Company&#148;) issued a press release announcing new data from the second cohort of its Phase 2 Clinical
Trial of <FONT STYLE="white-space:nowrap">ZGN-1061.</FONT> A copy of the press release is being furnished as Exhibit 99.1 to this Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> and is incorporated herein by reference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information in this Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> and Exhibit 99.1 attached hereto is intended to be furnished and shall not
be deemed &#147;filed&#148; for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference
in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Financial Statements and Exhibits. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000">Exhibit<br>No.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Description</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d655163dex991.htm">Press release issued by Zafgen, Inc. on January&nbsp;17, 2019, furnished herewith. </A></TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: January&nbsp;17, 2019</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>ZAFGEN, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Jeffrey Hatfield</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Jeffrey Hatfield</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d655163dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g655163g0117083914861.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Zafgen Announces Positive Results for Second Cohort </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>of Phase 2 Clinical Trial of <FONT STYLE="white-space:nowrap">ZGN-1061</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Data for the 1.8 mg dose demonstrated meaningfully greater efficacy than the 0.9 mg dose </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Cohort 2 data showed statistically and clinically significant 1.1% reduction of A1C at the 1.8 mg dose relative to placebo </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Progressive and notable body weight loss occurred at the 1.8 mg dose </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Results continue to support favorable safety and tolerability profile of <FONT STYLE="white-space:nowrap">ZGN-1061</FONT> </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Boston, Mass., January</B><B></B><B>&nbsp;17, 2019</B> &#150;Zafgen, Inc.&nbsp;(Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its
proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic diseases, today announced positive data for the second cohort of its Phase 2 clinical trial of
<FONT STYLE="white-space:nowrap">ZGN-1061,</FONT> designed to evaluate efficacy and safety in patients with type 2 diabetes and the likely therapeutic dose range of <FONT STYLE="white-space:nowrap">ZGN-1061</FONT> up to 1.8 mg. The clinical trial
met all of its primary objectives at the 1.8 mg dose, which included glycemic control, or change in A1C, and safety and tolerability. The <FONT STYLE="white-space:nowrap">12-week</FONT> data demonstrated that treatment with the 1.8 mg dose of <FONT
STYLE="white-space:nowrap">ZGN-1061</FONT> produced substantially more improvement in A1C than the 0.9 mg dose. Progressive and notable reduction in body weight also occurred in patients treated with the 1.8 mg dose. The data showed a favorable
safety and tolerability profile for <FONT STYLE="white-space:nowrap">ZGN-1061,</FONT> with no treatment-related serious adverse events and no cardiovascular (CV)&nbsp;safety signals observed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;The results we&#146;ve seen in our Phase 2 development of <FONT STYLE="white-space:nowrap">ZGN-1061,</FONT> and particularly with this latest 1.8 mg
dose cohort, appear very competitive with the currently available <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> anti-diabetes therapies,&#148; said Dennis Kim, M.D., Chief Medical Officer, Zafgen.
&#147;All of the pharmacological actions of <FONT STYLE="white-space:nowrap">ZGN-1061</FONT> improve at the 1.8 mg dose level and, with its insulin-sensitizing effects, we believe there is a clear opportunity for even greater benefit with longer
treatment duration given the effect we are seeing at just 12 weeks.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Treatment with <FONT STYLE="white-space:nowrap">ZGN-1061</FONT> demonstrated a
statistically significant reduction in A1C for 0.9 mg and 1.8 mg versus placebo at Week 12 (p=0.0003 and p&lt;0.0001, respectively), with a 1.1% reduction in A1C at the 1.8 mg dose relative to placebo. A1C levels continued to decline with no waning
of effect for both doses through Week 12. Progressive weight reduction was also observed at the 1.8 mg dose (p=0.0002), with placebo-corrected weight loss of 2.3 kg (5.1&nbsp;pounds) seen at Week 12 with no evidence of waning effect. Significant
improvements were observed across multiple secondary efficacy endpoints and various relevant metabolic biomarkers, as well. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">ZGN-1061</FONT> was generally safe and well-tolerated, with an adverse
event (AE) profile comparable to placebo. AEs were primarily mild to moderate, and there were no treatment-related serious AEs in the second cohort. The most frequent AEs at the 1.8 mg dose were upper respiratory tract infection, injection site
bruising, contusion and nasopharyngitis. There were no meaningful elevations in mean <FONT STYLE="white-space:nowrap">D-dimer</FONT> concentrations across the dosing groups, including 1.8 mg, as compared to baseline or placebo (excluding three
patients who experienced a hand fracture [placebo], gout [0.3 mg] and synovial rupture [1.8 mg] unrelated to treatment) and no CV safety signals observed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;For many people with type 2 diabetes, A1C levels are not adequately addressed by currently available treatments. MetAP2 inhibition offers a novel and
unique mechanism of action and a promising potential option in the treatment of this serious disease,&#148; said John Buse, M.D., Ph.D., Chief, Division of Endocrinology at the University of North Carolina School of Medicine. &#147;The significant
improvements in A1C and weight, two cornerstone pathology parameters of type 2 diabetes, coupled with very good tolerability and safety results for <FONT STYLE="white-space:nowrap">ZGN-1061,</FONT> are impressive at 12 weeks. So far, these results
look very encouraging.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zafgen previously reported positive full <FONT STYLE="white-space:nowrap">12-week</FONT> results for the initial cohort of
this Phase 2 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> clinical trial that included a range of doses up to 0.9 mg at the American Diabetes Association&#146;s&nbsp;78<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP>&nbsp;Scientific Sessions in June 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;While there are many treatments available to address type
2 diabetes, the bar is rising for new options and innovative mechanisms to address this complex disease and growing epidemic,&#148; said Jeffrey Hatfield, Chief Executive Officer, Zafgen. &#147;The profile of
<FONT STYLE="white-space:nowrap">ZGN-1061,</FONT> based on the Phase 2 clinical data, continues to align with our mission to bring safe, effective and potentially transformative treatments to patients who could benefit, and we believe these data
will strengthen the attractiveness of <FONT STYLE="white-space:nowrap">ZGN-1061</FONT> in our ongoing discussions with potential partners.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zafgen
expects to present full results of the Phase 2 clinical trial for <FONT STYLE="white-space:nowrap">ZGN-1061,</FONT> including the 1.8 mg dose cohort, at an upcoming medical meeting in 2019. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Zafgen </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zafgen&nbsp;(Nasdaq:ZFGN) is a
clinical-stage biopharmaceutical company leveraging its proprietary MetAP2 biology platform to develop novel therapies for patients affected by complex metabolic diseases.&nbsp;Zafgen&nbsp;has pioneered the study of MetAP2 inhibitors in both common
and rare metabolic disorders and is currently advancing programs for type 2 diabetes, Prader-Willi syndrome and liver diseases. Learn more at&nbsp;www.zafgen.com. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Safe Harbor Statement</B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Various statements in this release concerning&nbsp;Zafgen&#146;s&nbsp;future expectations, plans and prospects, may constitute forward-looking statements for
purposes of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements can be identified by terminology such as &#147;anticipate,&#148; &#147;believe,&#148;
&#147;could,&#148; &#147;could increase the likelihood,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;intend,&#148; &#147;is planned,&#148; &#147;may,&#148; &#147;should,&#148; &#147;will,&#148; &#147;will enable,&#148; &#147;would be
expected,&#148; &#147;look forward,&#148; &#147;may provide,&#148; &#147;would&#148; or similar terms, variations of such terms or the negative of those terms. Actual results may differ materially from those indicated by these forward-looking
statements as a result of various important factors, including, without limitation,&nbsp;Zafgen&#146;s&nbsp;ability to successfully engage with the FDA concerning the clinical hold on a clinical trial of
<FONT STYLE="white-space:nowrap">ZGN-1061,</FONT> Zafgen&#146;s ability to successfully demonstrate the efficacy and safety of <FONT STYLE="white-space:nowrap">ZGN-1061</FONT> and its other product candidates and to differentiate <FONT
STYLE="white-space:nowrap">ZGN-1061</FONT> and its other product candidates from first generation MetAP2 inhibitors, such as beloranib, the nonclinical and clinical results for <FONT STYLE="white-space:nowrap">ZGN-1061</FONT> and its other product
candidates, which may not support further development and marketing approval, actions of regulatory agencies, which may affect the initiation, timing and progress of nonclinical studies and clinical trials of its product
candidates,&nbsp;Zafgen&#146;s&nbsp;ability to obtain, maintain and protect its intellectual property,&nbsp;Zafgen&#146;s&nbsp;ability to enforce its patents against infringers and defend its patent portfolio against challenges from third parties,
competition from others developing products for similar uses, Zafgen&#146;s ability to manage operating expenses,&nbsp;Zafgen&#146;s&nbsp;ability to obtain additional funding to support its business activities and establish and maintain strategic
business alliances and new business initiatives when needed,&nbsp;Zafgen&#146;s&nbsp;dependence on third parties for development, manufacture, marketing, sales and distribution of product candidates, and unexpected expenditures, as well as those
risks more fully discussed in the section entitled &#147;Risk Factors&#148; in&nbsp;Zafgen&#146;s&nbsp;most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed with the&nbsp;Securities and Exchange Commission, as well as
discussions of potential risks, uncertainties, and other important factors in&nbsp;Zafgen&#146;s&nbsp;subsequent filings with the&nbsp;Securities and Exchange Commission, including without limitation Zafgen&#146;s Quarterly Reports on Form <FONT
STYLE="white-space:nowrap">10-Q.</FONT> In addition, any forward-looking statements represent&nbsp;Zafgen&#146;s&nbsp;views only as of today and should not be relied upon as representing its views as of any subsequent date.&nbsp;Zafgen explicitly
disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media/Investor
Relations Contacts: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Zafgen, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patricia Allen </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief Financial Officer </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">617-648-9792</FONT></FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Media </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Krystle Gibbs </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ten Bridge Communications </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">krystle@tenbridgecommunications.com </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">508-479-6358</FONT></FONT> </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investors </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">John Woolford </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Westwicke, An ICR Company </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>john.woolford@westwicke.com </U></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">443-213-0506</FONT></FONT> </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g655163g0117083914861.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g655163g0117083914861.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !A -<# 2(  A$! Q$!_\0
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M"BBB@ HHHH *BFM;>X_UT$<G^\H-2T4TVMA-)Z,J?V78?\^<'_?L4?V78?\
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7 "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
